Hounsom L, Tomlinson D R
Department of Pharmacology, Queen Mary and Westfield College, London, United Kingdom.
Clin Neurosci. 1997;4(6):380-9.
Defects of the peripheral nervous system are common in patients with diabetes mellitus. At least 50% of diabetic patients will develop a form of diabetic neuropathy within 25 years after diagnosis. Currently the cornerstone of treatment lies with the maintenance of euglycaemia using insulin, which has inherent problems of its own. In addition, the signs and symptoms of diabetic neuropathy are often intractable. Therefore, the development of effective treatments for diabetic neuropathy is urgently needed. Thus, animal models have been developed to investigate the pathogenesis of diabetic neuropathy and evaluate potential therapeutic agents. However, no model is perfect and no one would suggest that diabetic rats can replicate the human condition fully. In this review the appropriateness of established animal models of diabetic neuropathy is discussed with reference to the pathology and pathophysiology of the human case with the hope of addresssing some of the questions surrounding this general issue.
外周神经系统缺陷在糖尿病患者中很常见。至少50%的糖尿病患者在确诊后25年内会出现某种形式的糖尿病神经病变。目前,治疗的基石在于使用胰岛素维持血糖正常,但胰岛素本身存在一些问题。此外,糖尿病神经病变的体征和症状往往难以治疗。因此,迫切需要开发针对糖尿病神经病变的有效治疗方法。于是,人们建立了动物模型来研究糖尿病神经病变的发病机制并评估潜在的治疗药物。然而,没有一个模型是完美的,也没有人会认为糖尿病大鼠能完全复制人类的病情。在这篇综述中,我们将参照人类病例的病理学和病理生理学来讨论已建立的糖尿病神经病变动物模型的适用性,以期解决围绕这一普遍问题的一些疑问。